Abstract
The cellular protein “Bone marrow stromal antigen 2” (BST2 also called Tetherin, CD317, HM1.24) was identified as a major mediator of the innate immune defense against the dissemination of enveloped viruses. BST2 was shown to physically trap the de novo formed viral particles at the surface of infected cells, thereby reducing viral release. Lentiviruses have evolved specific strategies to down-regulate the expression level of BST2 from the surface of the cells and as such promote viral egress. In Human Immunodeficiency Virus-1 (HIV-1), the accessory protein Vpu counters BST2 antiviral activity. However, the cellular and molecular mechanisms involved are not fully understood. Vpumediated antagonism of BST2 antiviral activity seems to involve complex interplay between the viral protein and host components regulating protein turnover and vesicular trafficking. This review focuses on the interplay between Vpu and the ubiquitin/endosomal pathway in countermeasures of HIV-1 to BST2 restriction, with a particular emphasis on the “Endosomal Sorting Complexes Required for Transport” (ESCRT) machinery.
Keywords: BST2/Tetherin, Vpu, ESCRT, HRS, HIV-1, ubiquitinylation, degradation, cell surface down-regulation, endosome, CD4
Current HIV Research
Title:Role of the Endosomal ESCRT Machinery in HIV-1 Vpu-Induced Down- Regulation of BST2/Tetherin
Volume: 10 Issue: 4
Author(s): Katy Janvier, Nicolas Roy and Clarisse Berlioz-Torrent
Affiliation:
Keywords: BST2/Tetherin, Vpu, ESCRT, HRS, HIV-1, ubiquitinylation, degradation, cell surface down-regulation, endosome, CD4
Abstract: The cellular protein “Bone marrow stromal antigen 2” (BST2 also called Tetherin, CD317, HM1.24) was identified as a major mediator of the innate immune defense against the dissemination of enveloped viruses. BST2 was shown to physically trap the de novo formed viral particles at the surface of infected cells, thereby reducing viral release. Lentiviruses have evolved specific strategies to down-regulate the expression level of BST2 from the surface of the cells and as such promote viral egress. In Human Immunodeficiency Virus-1 (HIV-1), the accessory protein Vpu counters BST2 antiviral activity. However, the cellular and molecular mechanisms involved are not fully understood. Vpumediated antagonism of BST2 antiviral activity seems to involve complex interplay between the viral protein and host components regulating protein turnover and vesicular trafficking. This review focuses on the interplay between Vpu and the ubiquitin/endosomal pathway in countermeasures of HIV-1 to BST2 restriction, with a particular emphasis on the “Endosomal Sorting Complexes Required for Transport” (ESCRT) machinery.
Export Options
About this article
Cite this article as:
Janvier Katy, Roy Nicolas and Berlioz-Torrent Clarisse, Role of the Endosomal ESCRT Machinery in HIV-1 Vpu-Induced Down- Regulation of BST2/Tetherin, Current HIV Research 2012; 10 (4) . https://dx.doi.org/10.2174/157016212800792414
DOI https://dx.doi.org/10.2174/157016212800792414 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV vaccine development
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Development of NGR-Based Anti-Cancer Agents for Targeted Therapeutics and Imaging
Anti-Cancer Agents in Medicinal Chemistry A Review of Studies on Targeting Interleukin 4 Receptor for Central Nervous System Malignancy
Current Molecular Medicine Modular Protein Engineering in Emerging Cancer Therapies
Current Pharmaceutical Design Recent Advances in Superparamagnetic Iron Oxide Nanoparticles for Cellular Imaging and Targeted Therapy Research
Current Pharmaceutical Design The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy
Current Cancer Drug Targets Natural Sesquiterpenoids as Cytotoxic Anticancer Agents
Mini-Reviews in Medicinal Chemistry Pleiotropic Effects of Cardioactive Glycosides
Current Medicinal Chemistry PEGylation of Proteins and Liposomes: a Powerful and Flexible Strategy to Improve the Drug Delivery
Current Drug Metabolism Internal Ribosome Entry Site Elements in Eukaryotic Genomes
Current Genomics RBM15 Functions in Blood Diseases
Current Cancer Drug Targets Cinnamic Acid Derivatives in Tuberculosis, Malaria and Cardiovascular Diseases - A Review
Current Organic Chemistry Peptides to Target Tumor Vasculature and Lymphatics for Improved Anti-Angiogenesis Therapy
Current Cancer Drug Targets Antiviral Properties of Glycyrrhizic Acid and its Semisynthetic Derivatives
Mini-Reviews in Medicinal Chemistry Seek and Destroy: The Use of Natural Compounds for Targeting the Molecular Roots of Cancer
Current Drug Targets Electrochemotherapy in the Treatment of Kaposi’s Sarcoma: A Single Centre Cohort Study and a Comparison with the Literature Data
Current Cosmetic Science Combining Angiogenesis Inhibitors with Radiation: Advances and Challenges in Cancer Treatment
Current Pharmaceutical Design α-Secretase in Alzheimers Disease and Beyond: Mechanistic, Regulation and Function in the Shedding of Membrane Proteins
Current Alzheimer Research Recent Developments in Delivery of Nucleic Acid-Based Antiviral Agents
Current Pharmaceutical Design Molecular Markers of Glioblastoma and the Potential for Integration with Imaging: the Future for Assigning Prognosis and Best Treatment Strategy
Current Molecular Imaging (Discontinued) Src Family Kinases as Regulators of Angiogenesis: Therapeutic Implications
Current Cancer Therapy Reviews